Back to News
Market Impact: 0.3
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Phase 1 trial results showed cemsidomide combined with dexamethasone produced robust T-cell activation. The finding supports a key component of cemsidomide’s proposed dual mechanism of action and provides positive early-stage validation for the immunomodulatory therapy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Anthropic Goes Big on Compute, Microsoft Rethinks AI
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- ‘U.S. trade policy is damaging the U.S. auto industry’: Canada’s purchase of American cars hits new low as Trump’s tariffs backfire on U.S. automakers
- Why Microsoft Stock Is Up Today
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk